Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time

Unlike chemoimmunotherapy regimens, which are given for a defined period, ibrutinib, a first‐in‐class Bruton's kinase inhibitor, allows most patients with CLL to remain on treatment for an extended period. Our experience, supported by sequential CT scan images, suggests that long‐term ibrutinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Molica, Stefano, Carillio, Guido, Battaglia, Caterina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Image
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224778/
https://www.ncbi.nlm.nih.gov/pubmed/28096995
http://dx.doi.org/10.1002/ccr3.749
Descripción
Sumario:Unlike chemoimmunotherapy regimens, which are given for a defined period, ibrutinib, a first‐in‐class Bruton's kinase inhibitor, allows most patients with CLL to remain on treatment for an extended period. Our experience, supported by sequential CT scan images, suggests that long‐term ibrutinib promotes a high response rate that improves in quality with time.

Ejemplares similares